论文部分内容阅读
目的 探讨蚓激酶 Lum，抵可力得 (TIC)及三种剂量的阿斯匹林 (ASA)对康复期脑梗死病人缺血性卒中再发的预防作用。方法 对已患过脑梗死的病人 165例，随机分为 5组应用 ASA25mg/d、 50mg/d、 100mg/d、 TIC、 Lum进行缺血性卒中再发的预防性治疗。结果 与 ASA25mg/d组的每 100例月累积复发率 (7.75％ )相比， ASA 50mg/d(6.25％ ),相对危险性减少 20％ (RR I.25;95％ CI,0.73－ 1.25);ASA 100mg 12组 (4.75％ )， (RR1.70;95％ CL， 0.69～ 2.26);Lum 600mg/d组 (3.78％ )，相对危险减少 51.2％ (RR2.05;95％ CI， 1.1～ 3.80);TIC 250mg/d组相对危险性减少 41％； (3.52％ )，相对危险性减少 54.6％ (RR2.20;95％ CI,1.1～ 21.3)。结论 TIC250mg/d作为二级预防最为有效，除了传统的抗血小板剂外， Lum 600mg/d也可用作缺血性卒中的二级预防。
Objective To investigate the preventive effect of Lumbrokinase, Ticid, and three doses of aspirin (ASA) on recurrent ischemic stroke in patients with convalescent cerebral infarction. Methods A total of 165 patients with cerebral infarction were randomly divided into 5 groups: ASA25mg / d, 50mg / d, 100mg / d, TIC and Lum for prophylactic treatment of recurrent ischemic stroke. Results Compared with a cumulative recurrence rate (7.75%) for 100 mg / day of ASA at 25 mg / d, the relative risk decreased by 20% (RR 1.25; 95% CI, 0.73-1.25) (RR2.05; 95% CI, 1.1 ~ 1.1%) in the 600 mg / d group (3.78%) of ASA 100 mg group 12 (4.75% 3.80). The relative risk of TIC in 250 mg / d group decreased by 41% (3.52%) and the relative risk decreased by 54.6% (RR2.20; 95% CI, 1.1-21.3). Conclusion TIC 250mg / d is most effective as secondary prevention. In addition to traditional antiplatelet agents, Lum 600mg / d can also be used as secondary prevention of ischemic stroke.